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Angiogenesis, the formation of new blood vessels by sprouting from pre-existing endothelium, is a significant 
component in tumor progression. Marine natural products have been proved to be a rich source of novel compounds  
in drug discovery especially in the area of small molecule based targeted anticancer chemotherapeutics identification. 
Symbiotic actinomycetes from marine tunicates are having unique environmental niche that arise as a new and  
valuable source of inhibitors of angiogenesis. In the present study, actinomycetes strains were isolated from the areas of 
Muttom, Kanyakumari, Tamil Nadu, India and it was screened for the production of bioactive compounds.  
The bioactive compounds obtained were treated on zebrafish embryos at 50 % epiboly stage and maintained for  
72 hours post fertilization (hpf). RBC staining was done at 72 hpf to study the formation of blood vessel in embryos  
treated with biomolecules and RT-PCR was carried out to study mRNA expression of vascular endothelial growth  
factor (vegfaa) at 72 hpf. Biomolecules (T1 and T2) extracted from marine actinomyetes showed anti-angiogenic  
property by reducing the Intersegmental vessels (ISVs) (main angiogenic blood vessel) at 5 µM concentration.  
RT-PCR study reveals the reduction in mRNA expression of vegfaa. Our study emphasizes the importance of  
potential of anti-angiogenic compounds from marine tunicate symbiotic actinomycetes using zebrafish as in vivo  
model system.  
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Introduction 
Angiogenesis is a process of blood vessel 
formation from the pre-existing capillaries involved in 
physiological and pathological processes like embryo 
genesis, placentation, wound healing, inflammatory 
disorders and tumour growth1,2. Natural products play 
a crucial role in drug discovery and these are the 
sources for developing new drugs. Especially the 
marine actinobacteria are known to produce novel 
bioactive molecules in marine environment to protect 
themselves from predators. Studies by Folkman3 in 
1971 on angiogenesis research have paved the way 
for using marine bioactive molecules in the field of 
antiangiogenesis in the last three decades. Potential 
anti-angiogenic agents have been identified and 
extensively explored from marine organisms 
including sponges, sponge-associated bacteria, 
gorgonia, molluscs, soft coral and actinomycetes4. 
Bioactive compounds isolated from marine sources 
have become important in the study of antifungal, 
antibacterial, antiviral, anticancer, as well as anti-
coagulant properties5,6. 
Zebrafish exhibit highly characteristic blood-vessel 
patterning and a short period of development of blood 
vessels [i.e. 96 hours post-fertilization (hpf)]. 
Vasculogenesis in zebrafish is initiated as early as 12 
hpf, and by 24 hpf, a simple circulatory loop 
consisting of major vessel-like dorsal aorta and axial 
vein is established. By 24 hpf, development of 
angiogenic sprouts like the sub intestinal vessels 
(SIVs) is initiated to establish angiogenesis in the 
developing gut, allowing evaluation of anti-
angiogenic agents7. Hence, zebrafish paves way to 
perform systemic angiogenic assays. Further, 
zebrafish as a model organism exhibit genetic and 
functional conservation across angiogenic pathways. 
The major modulators of angiogenesis, tyrosine-
kinase domains of vascular endothelial growth factor 
receptor 2 (VEGFR2) and VEGF are also found to be 
conserved8,9. VEGF has been proved to be the 
fundamental mediator of physiological and 
pathological angiogenesis10. 
In the present study, zebrafish embryos were 
treated with bioactive compounds isolated from 




marine actinomycetes to study the anti-angiogenic 
property. We observed the survival rates induced by 
bioactive compounds, blood vessel formation using 
RBC staining and also to evaluate their anti-
angiogenic potential by reducing the expression of 
vegfaa, the major angiogenic determinant. 
 
Materials and Methods  
Zebrafish animal maintenance and embryo collection 
A re-circulating stand-alone system (Aquaneering, 
USA) was used to maintain zebrafish (3-5 months 
old) at 28 ºC with 10:14 h dark: light cycle11. During 
normal period, zebrafish were fed with flakes foods 
and during breeding period they were fed with blood 
worms, and brine shrimps. All protocols were 
reviewed and approved by Institutional Ethical 
Committee of Centre for Molecular and Nanomedical 
Research Unit, Sathyabama Institute of Science and 
Technology. 
Embryo collection was carried out using standard 
protocols from our previously published work12. 
Embryo medium (Hank’s medium) were prepared as 
per standard protocol of Kimmel et al.13, for culturing 
embryos. Embryos were collected at weekly intervals 
and various developmental stages were identified. The 
stages of development were fixed as hours of post 
fertilization (hpf)13. 
 
Separation of anti-angiogenic compounds 
Tunicate samples were collected from Muttom, 
Kanyakumari, Tamil Nadu, India at 8°07′48.00″ N 
Latitude and 77°19′12.00″ E Longitude and was 
grown in lab condition to generate actinomycetes. 
Bioactive molecules from actinomycetes were 
obtained by solvent separation and Column and TLC 
fractionation of small molecules was done using 
standard protocols14. 
 
Pre-treatment of samples 
Marine samples were rinsed with sterilized fresh 
seawater to remove loosely attached microorganisms 
and then subjected to dilution plate technique. 
Following this, the respective samples (tunicates) 
were cut down into small pieces (~1 cm X 3) and 
were homogenized in sterilized seawater. 
 
Isolation of actinomycetes 
One gram (1 g) of pre-treated samples were serially 
diluted in sterile sea water using serial dilution 
method and spread plated over the medium (Gause’s 
inorganic agar medium No. 1 Gause GF) containing 
soluble starch 20 g, KNO3 1 g, NaCl 0.5 g, K2HPO4 
0.5 g, MgSO4 0.5 g, FeSO4 20 µM and agar 15 g in 1 
L seawater. Plates were incubated at 28 ºC for 7-14 
days. Dry colonies of actinomycetes were selected 
and isolated. All the colonies growing on the 
petriplates were purified by repeated streaking on 
actinomycetes isolation medium. Actinomycetes 
isolation medium (AIM) slants were used for short 
time preservation of purified actinomycetes14. For 
long term preservation, the purified actinomycetes 
were inoculated in AIM broth and were incubated at 
28 ºC for 7-14 days. From this broth 20 % glycerol 
stocks were prepared and stored at -20 ºC. 
 
Fermentation and extraction 
Single colony of isolated actinomycetes cultures 
were streaked on the AIM medium and incubated for 
7 days. After 7 days, the medium was cut into small 
pieces and were placed in 500 ml Erlenmeyer flask 
containing equal volume of ethyl acetate (cold 
percolation method). The flask was kept in the shaker 
for 24 hours at 220 rpm. The organic crude extract 
was filtered using Whattman No. 1 filter paper. The 
organic solvents were evaporated and the crude 
extract was concentrated in vacuum concentrator 
(Eppendorf 5301) at 45 ºC. 
 
Treatment of biomolecules and morphological observations 
The extracted biomolecules from actinomycetes 
(T1, T2) were dissolved in 0.1 % DMSO and treated 
with various concentrations (1 µg, 2.5 µg, 5 µg,  
7.5 µg and 10 µg) to the embryo media where the 
embryos were staged and sorted at 50 % epiboly in a 
6 well culture plate. The experiments were performed 
with 120 embryos (20 embryo × 6 wells) for each 
concentration of biomolecules and control embryos 
were treated with 0.1 % DMSO in 2 ml Embryo 
medium only. Embryos were visually inspected for 
viability/survival rate. 
 
Anti-angiogenic activity of bioactive compound -RBC staining 
Embryos treated with various concentrations of 
biomolecules (T1 and T2) and control at 50 % epiboly 
stage, were subjected to RBC staining at 72 hpf using 
standard protocols from previous published work12,15.  
 
Total RNA extraction and reverse transcription 
RNA was isolated from embryos [treated with 
compounds (T1, T2) and control embryos] at 72 hpf 
and reverse transcribed using standard protocols from 
our previous research work12. Conditions for PCR are 
mentioned in Table 1 and primers sequences used in 
the study were obtained from Sigma (Table 2).  





Isolation and screening of Actinomycetes 
Two different actinomycetes strains (T1, T2) were 
isolated from the marine tunicates using standard 
medium. The pure cultures of these strains were 
maintained as slants with starch casein agar medium 
and these slants were preserved at 40 °C. These two 
strains were screened for the production of bioactive 
compounds. The extracts were directly tested on 
zebrafish embryos for anti-angiogenic activity. 
 
Morphological observations of zebrafish  
The embryos of the control group developed 
normally in embryo medium, and hatching began at 
48 hpf and completed at 72 hpf. The survival rates of 
zebrafish embryos treated with various concentrations 
of biomolecules (T1 & T2) for 24, 48 and 72 hpf were 
recorded (Fig. 1). The compounds didn’t show any 
significant lethal effect on zebrafish embryos. 
 
Blood vessel imaging 
RBC staining at 72 hpf revealed the absence of major 
angiogenic vessels namely the Inter segmental vessels 
(ISVs) in developing embryos on treatment with 
biomolecule extracts namely T1, T2. Control embryos 
formed with normal vasculature is shown in Figure 2(A 
& C), whereas embryos treated with biomolecules 
developed with poor vasculature or moderated ISV 
formation is shown in Figure 2 (B & D). Magnified 
image of stained vessels is shown in Figure 3. 
 
mRNA expression of VEGF when treated with biomolecules at 
72 hpf 
The potential of biomolecules extracted to decrease 
the expression of vegfaa, at its mRNA level was 
analyzed using Reverse Transcriptase PCR. Figure 4 
depicts the PCR products of vegfaa when treated with 
Extract 1 (T1) and Extract 2 (T2) at various 
concentrations (1 µg, 2.5 µg, 5 µg, 7.5 µg and 10 µg) 
and control (0.1 % DMSO in EM). Results show that 
extracts have the potential to down regulate the level 
of mRNA expression of vegfaa at 5 µg and 10 µg of 
T1 and T2 treated embryos respectively. The RT-PCR 
analysis indicated that extracted biomolecules can 
inhibit new blood vessel formation by down 
regulating main angiogenic growth factor VEGF. 
 
Discussion  
In recent years, small molecule therapeutics design 
and development to inhibit angiogenesis has gained 
considerable importance in anti-angiogenesis 
research. Actinobacteria from marine environment are 
known to produce the most efficient groups of 
secondary metabolites and most of them are 
biologically active. Studies involving actinobacteria from 
terrestrial sources since 1950s have been screened 
Table 2 — Primers used in the study 
Primer name Forward Reverse Product size (bp) 
vegfaa 5’-ctcctccatctgtctgctgtaaag- 3’ 5’-ctctctgagcaaggctcacag-3’ 398 
β-actin 5’-tccccttgttcacaataacc-3’ 5’-tctgttggctttgggattc-3’ 223 
Table 1 — PCR condition for vegfaa 
Condition Temperature Duration 
Initial denaturation 95 °C 4 minutes 
Denaturation  for 95 °C 30 seconds 
30 seconds        35 cycles 
30 seconds 
Annealing 54 °C 
Extension  72 °C 
Final extension  72 °C 7 minutes 
 
 
Fig. 1 — Survival rates of embryos treated with biomolecules 
extracted 





for many important antitumor, anticancer, antibiotics 
and immunosuppressive agents16. Many of the 
antitumor compounds from marine drugs are mainly 
derived from marine actinobacteria and these 
metabolites play an essential role in identification of 
pharmaceutical compounds17. The biomolecules (T1 
and T2) extracted from marine actinomycetes in our 
study showed anti-angiogenic property by reducing 
the ISVs in 72hpf zebrafish embryos which was 
confirmed using RBC staining and the extracts T1 and 
T2 also reduced the mRNA expression of vegfaa at 
micromolar concentrations in zebrafish embryos. 
These results are correlated with our previous studies 
using methyxanthine pentoxifylline and resveratrol in 
zebrafish model12,18. 
Our work elucidates that the zebrafish is a suitable 
model for small molecules screening that can inhibit 
angiogenesis and it shares a high level of physiologic 
and genetic homology with humans, including 
digestive tract, brain, vasculature, musculature, and an 
innate immune system19-24. In the last decade, these 
advantages of zebrafish model in research have 
proved to be superior for use in cancer research. 
Long-standing methods for developing a zebrafish 
cancer model including transgenic regulation, 
carcinogenic treatment, and the transplantation of 
mammalian tumor cells25 are well established in 
recent years. This made us to attempt to discover 
novel biomolecules from marine sources to study anti-
angiogenic activity.  
 
Summary and Conclusion 
We investigated the anti-angiogenic potential of 
small molecules extracted from marine tunicates 
using zebrafish model. However, there is a need to 
develop assay/screening strategies. The identified 
small molecules coupled with biochemical and 
molecular methods in zebrafish would provide a 
platform to address various developmental and 
disease processes. Biomolecules from tunicates could 
possibly inhibit angiogenesis by decreasing the main 
angiogenic vessel namely the ISVs. Biomolecules 
extracted also found to suppress vegf mediated 
signaling pathway by down-regulating the gene 
expression of vegfaa at micromolar concentration. 
Further work has to be carried out to purify and 
predict the structural novelty of the compound(s). 
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Fig. 2 — RBC staining: (A & C) Control embryos; and (B & C) 
Decreased ISV formation is observed at 5 μM of treated 
compounds (indicated by arrows) compared with control 
 
 





Fig. 4 — Expression of vegfaa after 72 hours incubation of 
extracts (T1, T2) 
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